The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK
Abstract
Introduction. This study endeavors to analyze the effects of miR-1204 on the expression of DEK oncogene in non-small cell lung cancer (NSCLC) cell lines and to study the molecular mechanisms of these effects.
Material and methods. The miR-1204 mimics and inhibitors were transfected into the (A549 and SPC) NSCLC cells. Then the mRNA levels, cell viability, apoptosis rate, morphology and caspase activity were determined. The expression of apoptosis-related proteins Bcl-2 and Bax was also analyzed.
Results. In NSCLC cell lines (A549 and SPC), DEK mRNA levels were down-regulated in miR-1204 overexpression group. In miR-1204 inhibition group, the expression of DEK mRNA showed an opposite trend. The overexpression of miR-1204 increases the apoptosis rate in NSCLC cells. The Bcl-2 levels in the miR-1204 overexpression group were decreased, while the Bax level was increased. In the miR-1204 inhibition group, expression of Bcl-2 and Bax showed opposite trends. Cell staining revealed cell’s morphological changes; the apoptosis in the miR-1204 overexpression group revealed significant morphological features, such as brighter nuclei and nuclear condensation. Results indicated a typical characteristic of apoptosis in the miR-1204 overexpression group. Caspase-9 and Caspase-3 were involved in the apoptosis pathway, which was mediated by miR-1204 and DEK.
Conclusions. The miR-1204 induces apoptosis of NSCLC cells by inhibiting the expression of DEK. The mechanism of apoptosis involves down-regulation of Bcl-2 and up-regulation of Bax expression. Moreover, the apoptosis was mediated by mitochondria-related caspase 9/3 pathway.
Keywords: NSCLCA549 cellsSPC cellsDEKmiR-1204apoptosisBcl-2Baxcaspase-3caspase-9
References
- Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005; 172(5): 523–529.
- Katanoda K, Yako-Suketomo H. Trends in lung cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol. 2012; 42(3): 239–240.
- Guttmann DM, Kobie J, Grover S, et al. National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. Head Neck. 2018; 40(6): 1147–1155.
- Fitzmaurice C, Allen C, Barber RM, et al. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3(4): 524–548.
- Han R, Zheng R, Zhang S, et al. [Trend analyses on the differences of lung cancer incidence between gender, area and average age in China during 1989-2008]. Zhongguo Fei Ai Za Zhi. 2013; 16(9): 445–451.
- Alexiadis V, Waldmann T, Andersen J, et al. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev. 2000; 14(11): 1308–1312.
- Lin L, Piao J, Gao W, et al. DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 2013; 13: 366.
- Piao J, Shang Y, Liu S, et al. High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol. 2014; 9: 67.
- Lin D, Dong X, Wang K, et al. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 2015; 6(3): 1806–1820.
- Liu S, Wang X, Sun F, et al. DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int. 2012; 62(3): 176–181.
- Datta A, Adelson ME, Mogilevkin Y, et al. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 2011; 11: 234.
- Ashkenazi A, Fairbrother WJ, Leverson JD, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017; 16(4): 273–284.
- Yu Le, Huang X, Zhang W, et al. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2016; 7(18): 26844–26855.
- Feng T, Liu Y, Li C, et al. DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis. Tumour Biol. 2017; 39(7): 1010428317716248.
- Liu X, Qi D, Qi J, et al. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma. Oncol Rep. 2016; 35(1): 155–162.
- Liu Y, Han Y, Zhang Hu, et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One. 2012; 7(12): e52280.
- Peck BC, et al. E, Sincavage J, Feinstein S miR-30 Family Controls Proliferation and Differentiation of Intestinal Epithelial Cell Models by Directing a Broad Gene Expression Program That Includes SOX9 and the Ubiquitin Ligase Pathway. J Biol Chem. ; 291(31): 15975–15984.
- Nie JH, Chen ZH, Shao CL, et al. Analysis of the miRNA-mRNA networks in malignant transformation BEAS-2B cells induced by alpha-particles. J Toxicol Environ Health A. 2016; 79(9-10): 427–435.
- Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010; 18(9): 1650–1656.
- Wang Z, Liao H, Deng Z, et al. miRNA-205 affects infiltration and metastasis of breast cancer. Biochem Biophys Res Commun. 2013; 441(1): 139–143.
- Yao Yu, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009; 2(6): 963–970.
- Chen Z, Zeng H, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010; 29: 151.
- Wang ZX, Bian HB, Wang JR, et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011; 104(7): 847–851.
- Salim H, Akbar NS, Zong D, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012; 107(8): 1361–1373.
- Wang H, Zhu Y, Zhao M, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One. 2013; 8(8): e70192.
- Jiang W, He Y, Shi Y, et al. MicroRNA-1204 promotes cell proliferation by regulating PITX1 in non-small-cell lung cancer. Cell Biol Int. 2019; 43(3): 253–264.
- Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116(2): 205–219.
- Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008; 9(1): 47–59.
- Dejean LM, Martinez-Caballero S, Guo L, et al. Oligomeric Bax is a component of the putative cytochrome c release channel MAC, mitochondrial apoptosis-induced channel. Mol Biol Cell. 2005; 16(5): 2424–2432.
- Saba JD, Obeid LM, Hannun YA. Ceramide: an intracellular mediator of apoptosis and growth suppression. Philos Trans R Soc Lond B Biol Sci. 1996; 351(1336): 233–40; discussion 240.
- García S, Liz M, Gómez-Reino JJ, et al. Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Res Ther. 2010; 12(1): R33.
- Rahman MdA, Kim NH, Huh SO. Cytotoxic effect of gambogic acid on SH-SY5Y neuroblastoma cells is mediated by intrinsic caspase-dependent signaling pathway. Mol Cell Biochem. 2013; 377(1-2): 187–196.
- Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovasc Res. 2012; 96(1): 32–37.
